In the context of searching for acquired resistance mechanism in oncogene-addicted cancers, the value of plasma testing is more evident but the capacity to capture fusions remains a key consideration as fusions are being increasingly recognized as resistance mechanisms to third-generation EGFR-inhibitors, notably [23,24]. This evidence concerns the gene EGFR and cancer.